ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
AtriCure Inc

AtriCure Inc (ATRC)

36.055
-0.145
( -0.40% )
Updated: 09:59:00

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
36.055
Bid
36.00
Ask
36.16
Volume
72,333
35.63 Day's Range 36.38
18.94 52 Week Range 42.9999
Market Cap
Previous Close
36.20
Open
36.18
Last Trade
1
@
36.0703
Last Trade Time
09:58:59
Financial Volume
US$ 2,606,157
VWAP
36.03
Average Volume (3m)
582,095
Shares Outstanding
48,753,251
Dividend Yield
-
PE Ratio
-57.60
Earnings Per Share (EPS)
-0.62
Revenue
399.25M
Net Profit
-30.44M

About AtriCure Inc

AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft T... AtriCure Inc is a innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
-
AtriCure Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker ATRC. The last closing price for AtriCure was US$36.20. Over the last year, AtriCure shares have traded in a share price range of US$ 18.94 to US$ 42.9999.

AtriCure currently has 48,753,251 shares outstanding. The market capitalization of AtriCure is US$1.76 billion. AtriCure has a price to earnings ratio (PE ratio) of -57.60.

ATRC Latest News

AtriCure to Participate in the Stifel 2024 Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

AtriCure Reports Third Quarter 2024 Financial Results

Worldwide revenue of $115.9 million – an increase of 17.9% year over year U.S. revenue of $95.5 million – an increase of 16.8% year over year Achieved 20% growth on revenues from open appendage...

AtriCure to Participate in the UBS Global Healthcare Conference

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management...

AtriCure to Announce Third Quarter 2024 Financial Results

  AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain...

AtriCure a obtenu la certification de marquage CE pour la pince EnCompass®

Une approbation qui sert de nouveau vecteur de croissance à l'international pour AtriCure AtriCure, Inc. ( Nasdaq: ATRC ), leader en matière d'innovation pour les interventions chirurgicales et...

AtriCure erhält CE-Kennzeichnung für die EnCompass®-Klemme

Die Zulassung ist ein neuer Katalysator für das internationale Wachstum von AtriCure AtriCure, Inc. (Nasdaq: ATRC), ein führender Innovator im Bereich chirurgischer Behandlungen und Therapien...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.385-3.6992521367537.4438.3435.6343576236.95766504CS
46.88523.603016798129.1738.3427.6471072832.980996CS
1212.08550.417188151923.9738.3423.9758209529.69450498CS
2613.20557.789934354522.8538.3418.9472400125.23206765CS
52-2.145-5.6151832460738.242.999918.9470792528.13254292CS
156-41.775-53.67467557577.8379.62518.9443173037.13686042CS
2607.94528.263963002528.1189.1818.9439747942.34803063CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
PULMPulmatrix Inc
US$ 6.04
(69.66%)
9.63M
OMEROmeros Corporation
US$ 6.99
(66.83%)
8.06M
MTEMMolecular Templates Inc
US$ 0.47465
(47.36%)
2.96M
QUBTQuantum Computing Inc
US$ 3.90
(46.62%)
123.96M
GORVLazydays Holdings Inc
US$ 1.24
(34.78%)
184.68k
SOWGSow Good Inc
US$ 4.25
(-56.68%)
1.18M
NVCTNuvectis Pharma Inc
US$ 6.10
(-42.83%)
1.02M
TRNRInteractive Strength Inc
US$ 3.77
(-35.33%)
1.05M
MFHMercurity Fintech Holding Inc
US$ 3.745
(-31.28%)
206.41k
JTAIJet AI Inc
US$ 5.625
(-30.73%)
226.97k
ELABElevai Labs Inc
US$ 0.0275
(11.34%)
1.37B
XTIAXTI Aerospace Inc
US$ 0.0765
(33.74%)
276.31M
SVMHSRIVARU Holding Ltd
US$ 0.02988
(23.47%)
194.87M
QUBTQuantum Computing Inc
US$ 3.90
(46.62%)
123.96M
MVSTMicrovast Holdings Inc
US$ 0.8656
(8.87%)
123.5M

ATRC Discussion

View Posts
mlkrborn mlkrborn 11 years ago
HISTORY
Initial Public Offering



On August 10, 2005, we consummated an initial public offering of 4.6 million shares of our common stock at $12.00 per share, which includes the underwriters exercise of their over-allotment option, on August 9, 2005, to purchase 600,000 shares of our common stock of which 450,000 shares were sold by selling shareholders and 150,000 shares were sold by us. We did not receive any proceeds from the sale of the 450,000 shares of common stock that were sold by selling shareholders. These share amounts reflect a 1-for-3.8 reverse split of our capital stock that was effected on July 27, 2005. Proceeds to us from the offering, after deducting underwriting discounts and commissions but before expenses, were $46.3 million. Expenses are estimated to be approximately $3.25 million.



15
👍️0
mlkrborn mlkrborn 11 years ago
AtriCure receives FDA approval for investigational study to evaluate stroke prevention in atrial fibrillation (ATRC) 14.35 : Co announces the FDA approval to begin enrollment in a clinical study of AtriCure's AtriClip Left Atrial Appendage Exclusion System. The study will evaluate the use of the AtriClip device to prevent stroke in patients with Afib. The feasibility study will enroll Afib patients at seven medical centers across the country. The study will focus on patients with risk factors that place them at significant risk of stroke as well as substantial bleeding risks that contraindicate them for anticoagulation therapy. Research suggests that up to 40% of patients are unable to take oral anticoagulants due to excessive risk of bleeding.
👍️0
dmarkg dmarkg 12 years ago
Hey Wobblenuts and Jackie Scan I want to show you something....

Medical Breakthrough Wound Stasis Technology

ATRC and EPGL could possibly go hand in hand here...
Merry Christmas 2012

Merry Chirstmas 2012, friends.
👍️0
wobblenuts wobblenuts 12 years ago
Any talks involving ATRC and soon to be sub penny wonder EPGL?



Are they hinting at something here?


1)"ATRC fully SEC reporting financials are available at OTCMARKETS for EPGL investors to see as an example of where EPGL management is headed."

2)"EPGL initiating R&D on 4 new medical devices before end of 2012."

3)"Property and equipment, net 0"
👍️0
Penny Roger$ Penny Roger$ 13 years ago
~ Monday! $ATRC ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $ATRC ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=ATRC&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=ATRC&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=ATRC
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=ATRC#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=ATRC+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=ATRC
Finviz: http://finviz.com/quote.ashx?t=ATRC
~ BusyStock: http://busystock.com/i.php?s=ATRC&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=ATRC >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.
👍️0
Penny Roger$ Penny Roger$ 13 years ago
AtriCure, Inc., is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage. The Company has two primary product lines for the ablation of cardiac tissue. Its primary product line, which accounts for a majority of its revenues, is Isolator Synergy bipolar ablation clamp system (Isolator system) and related radiofrequency ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. In addition, it offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to exclude the left atrial appendage.

http://www.google.com/finance?q=ATRC
👍️0